A Study of LY4515100 in Healthy Participants
A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY4515100 in Healthy Participants and an Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of LY4515100 and of LY4515100 on the Pharmacokinetics of CYP and Transporter Substrates in Healthy Participants
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: LillyTrials@Lilly.com
Study Contact Backup
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75247
- Recruiting
- Fortrea Clinical Research Unit
-
Principal Investigator:
- Gene Voskuhl
-
Contact:
- Phone Number: 866-429-3700
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Recruiting
- Fortrea Clinical Research Unit
-
Principal Investigator:
- Kimberly Cruz
-
Contact:
- Phone Number: 866-429-3700
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
-
Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
-
Individuals not of childbearing potential (INOCBP) may participate in this trial.
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- must be 18 to 45 years of age (inclusive).
- have a BMI within the range of 18.5 to 30 kg/m².
- may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion Criteria:
-
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
-
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
-
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
-
Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
-
Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
-
increases the risks associated with participating in the study
-
may confound ECG data analysis
-
Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
-
Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
-
Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
-
Show evidence of
-
Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
-
hepatitis C and/or positive hepatitis C antibody
-
hepatitis B and/or positive hepatitis B surface antigen.
-
Have liver disease.
-
Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
-
Part C Only:
- Have history of neuropathy of any cause.
- Have impaired hearing or a history of hearing problems.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
- Participants with any known history of thyroid disease
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
- Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
- Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
- Have undiagnosed abnormal uterine bleeding.
- Have any history of breast, uterine or ovarian cancer.
- Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
- Have contraindications for the use of levonorgestrel/ethinyl estradiol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LY4515100 of Part A (SAD)
Single-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 of Part B (MAD)
Multiple-ascending doses of LY4515100 will be given orally |
given orally |
|
Experimental: LY4515100 and Itraconazole of Part C
LY4515100 and Itraconazole will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Metformin of Part C
LY4515100 and Metformin will be given orally |
given orally given orally |
|
Experimental: LY4515100 and Transporter Substrates or Renal Marker of Part C
LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
given orally given orally given orally given IV given orally |
|
Experimental: LY4515100 and Midazolam of Part C
LY4515100 will be given orally. Midazolam will be given orally and IV. |
given orally given orally given IV |
|
Experimental: LY4515100 and Combined Oral Contraceptive of Part C
LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally |
given orally given orally given orally |
|
Placebo Comparator: Placebo Part A
Placebo will be given orally |
given orally |
|
Placebo Comparator: Placebo Part B
Placebo will be given orally |
given orally |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
Time Frame: Day 1 up to Day 30
|
SAEs of LY4515100 |
Day 1 up to Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Time Frame: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
Time Frame: Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
Time Frame: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
Time Frame: Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
Time Frame: Day 1 through Day 11
|
PK: AUC of LY4515100 |
Day 1 through Day 11
|
|
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
Time Frame: Day 1 through Day 11
|
PK: Cmax of LY4515100 |
Day 1 through Day 11
|
|
PK: Time of maximum observed drug concentration (tmax) of LY4515100
Time Frame: Day 1 through Day 11
|
PK: tmax of LY4515100 |
Day 1 through Day 11
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Azoles
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Carboxylic Acids
- Alkaloids
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glycosides
- Amides
- Purinones
- Purines
- Pyrimidines
- Steroids
- Fused-Ring Compounds
- Benzene Derivatives
- Hydrocarbons, Halogenated
- Benzazepines
- Estradiol Congeners
- Gonadal Steroid Hormones
- Gonadal Hormones
- Biguanides
- Guanidines
- Amidines
- Acids, Carbocyclic
- Sulfonamides
- Sulfones
- Benzoates
- Benzodiazepines
- Triazoles
- Fluorobenzenes
- Hydrocarbons, Fluorinated
- Piperazines
- Norpregnenes
- Norpregnanes
- Norsteroids
- Xanthines
- Triiodobenzoic Acids
- Iodobenzoates
- Digitalis Glycosides
- Cardenolides
- Cardiac Glycosides
- Cardanolides
- Norpregnatrienes
- Estrogenic Steroids, Alkylated
- Norgestrel
- Rosuvastatin Calcium
- Midazolam
- Digoxin
- Metformin
- Caffeine
- Itraconazole
- Levonorgestrel
- Ethinyl Estradiol
- Iohexol
Other Study ID Numbers
Other Study ID Numbers
- 27789
- J6V-MC-OIAB (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.